Adult Myelodysplastic Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patient was initially diagnosed with low-risk myelodysplastic syndrome-refractory cytopenias and multilineage dysplasia (MDS-RCMD), progressed to AML after failing hypomethylating agent therapy.
|
28187034 |
2019 |
Adult Myelodysplastic Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.
|
27694924 |
2017 |
Adult Myelodysplastic Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
From this analysis, we identified a novel case of a donor-derived myelodysplastic syndrome in an HSCT recipient that is consistent with clonal evolution of TET2-mutated clonal hematopoiesis of indeterminate potential (CHIP) within the donor.
|
27497531 |
2016 |
Adult Myelodysplastic Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
A zebrafish model of myelodysplastic syndrome produced through tet2 genomic editing.
|
25512612 |
2015 |
Adult Myelodysplastic Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.Blood 2014 Oct 23;124(17):2705-12.
|
25697572 |
2015 |
Adult Myelodysplastic Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutation status of TET2, IDH1 and IDH2 was investigated in a cohort of 46 paired myelodysplastic syndrome/acute myeloid leukemia samples and 122 non-paired cases with de novo myelodysplastic syndrome, to clarify their roles in the evolution of myelodysplastic syndrome to acute myeloid leukemia.
|
23996483 |
2014 |
Adult Myelodysplastic Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
|
25224413 |
2014 |
Adult Myelodysplastic Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recurrent deletions and somatic mutations in TET2, a gene involved in epigenetic regulation, have been reported in about 20% of adult patients with myelodysplastic syndrome.
|
24301955 |
2013 |
Adult Myelodysplastic Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Detection of TET2 abnormalities by fluorescence in situ hybridization in 41 patients with myelodysplastic syndrome.
|
22749034 |
2012 |
Adult Myelodysplastic Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent findings of mutated IDH1, IDH2, DNMT3A or TET2 in myelodysplastic syndrome/acute myeloid leukaemia patients underscore this notion, and point to the importance of epigenetic changes for developing tumour cells.
|
22712628 |
2012 |
Adult Myelodysplastic Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutations of the ten eleven translocation 2 gene (TET2) have recently been reported in myelodysplastic syndrome and myeloproliferative neoplasms.
|
20489055 |
2010 |
Adult Myelodysplastic Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Seventy-one TET2 mutations, with a relative mutation abundance (RMA) ≥ 10%, were identified in 39 of 320 (12%) myelodysplastic syndrome and 16 of 35 (46%) chronic myelomonocytic leukemia patients (P < .001).
|
20693430 |
2010 |
Adult Myelodysplastic Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome.
|
19528370 |
2009 |